ROS1
About
Location: 6q22.1
Mappings
Biomarkers
ROS1 is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| Wild type ROS1 | Wild type | 3 | 3 |
| v::ROS1 | Rearrangement | 4 | 7 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed | |
| EMA (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Cemiplimab | |
| EMA (1) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed | |
| EMA (1) FDA (1) | v::ROS1 | Non-Small Cell Lung Cancer | Crizotinib | |
| EMA (1) FDA (1) | v::ROS1 | Non-Small Cell Lung Cancer | Entrectinib | |
| EMA (1) FDA (1) | v::ROS1 | Non-Small Cell Lung Cancer | Repotrectinib | |
| FDA (1) | v::ROS1 | Non-Small Cell Lung Cancer | Taletrectinib |